Takanobu Maekawa1, Yukihiro Ohya2, Masashi Mikami3, Satoko Uematsu4, Akira Ishiguro5. 1. Division of Pediatrics, Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan. 2. Division of Allergy, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan. 3. Division of Biostatistics, Center for Clinical Research, National Center for Child Health and Development, Tokyo, Japan. 4. Division of Emergency Service and Transport Medicine, Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan. 5. Department of Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan.
Abstract
INTRODUCTION: The Modified Pulmonary Index Score (MPIS) was developed as an objective assessment tool for acute asthma exacerbation in children. Although it is considered reliable, there are no known studies of its clinical utility. The objective of this study was to evaluate the validity of the MPIS for children with acute asthma in a clinical setting. METHODS: In this retrospective study conducted between July 2009 and June 2011 using electronic medical records at the emergency department of a single pediatric medical center in Tokyo, Japan, the MPIS was recorded for patients with acute asthma at initial assessment and after treatment with an inhaled beta-agonist. We evaluated the responsiveness and predictive validity of the MPIS using disposition as an outcome. RESULTS: A total of 2242 patients were assessed using the MPIS (median age, 3 years; 71.2% patients were 5 years or younger). The mean (SD) MPIS at initial assessment was 7.1 (3.6) and was significantly higher for the admission group than for the non-admission group (9.9 [2.9] vs. 5.9 [3.1]; P < 0.001). The receiver operator characteristic curve of the initial MPIS for hospital admission demonstrated moderate predictive ability (area under the curve, 0.83). An MPIS reduction of 3 or more indicated a clinically significant change when the MPIS at initial assessment was between 6 and 10 (risk ratio for admission [95% CI], 0.41 [0.28-0.60]; P < 0.001). CONCLUSION: The MPIS demonstrated good concurrent validity, predictive validity, and responsiveness in a wide range of clinical settings.
INTRODUCTION: The Modified Pulmonary Index Score (MPIS) was developed as an objective assessment tool for acute asthma exacerbation in children. Although it is considered reliable, there are no known studies of its clinical utility. The objective of this study was to evaluate the validity of the MPIS for children with acute asthma in a clinical setting. METHODS: In this retrospective study conducted between July 2009 and June 2011 using electronic medical records at the emergency department of a single pediatric medical center in Tokyo, Japan, the MPIS was recorded for patients with acute asthma at initial assessment and after treatment with an inhaled beta-agonist. We evaluated the responsiveness and predictive validity of the MPIS using disposition as an outcome. RESULTS: A total of 2242 patients were assessed using the MPIS (median age, 3 years; 71.2% patients were 5 years or younger). The mean (SD) MPIS at initial assessment was 7.1 (3.6) and was significantly higher for the admission group than for the non-admission group (9.9 [2.9] vs. 5.9 [3.1]; P < 0.001). The receiver operator characteristic curve of the initial MPIS for hospital admission demonstrated moderate predictive ability (area under the curve, 0.83). An MPIS reduction of 3 or more indicated a clinically significant change when the MPIS at initial assessment was between 6 and 10 (risk ratio for admission [95% CI], 0.41 [0.28-0.60]; P < 0.001). CONCLUSION: The MPIS demonstrated good concurrent validity, predictive validity, and responsiveness in a wide range of clinical settings.
Authors: Y Iikura; T Matsumoto; K Fujita; T Otsuka; Y Sakamoto; S K Yun; H Saito; T Obata; A Akasawa; M C Capulong; N Sakaguchi; Y Oya; K Tahara; H Tachimoto; H Kawahara; N Koya Journal: Int Arch Allergy Immunol Date: 1997 May-Jul Impact factor: 2.749